相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High Fat Diet Partially Attenuates Fermentation Responses in Rats Fed Resistant Starch from High-Amylose Maize
Jason A. Charrier et al.
OBESITY (2013)
Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue
Ganesh V. Sangle et al.
ENDOCRINOLOGY (2012)
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
Dominique Xavier Brown et al.
JOURNAL OF NUTRITION AND METABOLISM (2012)
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
Alan J. Garber
DIABETES CARE (2011)
DPP-4 inhibitors: What may be the clinical differentiators?
John Gerich
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results
Sten Madsbad
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Michael Boschmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat
Michael J. Keenan et al.
OBESITY (2006)
Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system
T Osaka et al.
PEPTIDES (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
SL Conarello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
D Marguet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
